Disease: Polycythemia vera
- <em>TTN</em>-related hereditary myopathy with early respiratory failure presented with elevated hemoglobin initially: A case report and literature review
- 10-year success story in CTEPH treatment: breaking the myth of rareness
- A case report and literature review of IgA nephropathy presenting as nephrotic syndrome in polycythemia vera
- A comparison between erythrocytapheresis and venesection for the treatment of JAK2-mutated polycythaemia
- A germline <em>JAK2</em> exon12 mutation and a late somatic <em>CALR</em> mutation in a patient with essential thrombocythemia
- A lasso and random forest model using flow cytometry data identifies primary myelofibrosis
- A Phase I Trial Evaluating the Addition of Lenalidomide to Patients with Relapsed/Refractory Multiple Myeloma Progressing on Ruxolitinib and Methylprednisolone
- A Review About the Assessment of the Bleeding and Thrombosis Risk for Patients With Myeloproliferative Neoplasms Scheduled for Surgery
- A safety evaluation of ruxolitinib for the treatment of polycythemia vera
- Activated PRKCD-mediated neutrophil extracellular traps pathway may be the prothrombotic mechanism of neutrophils in polycythemia vera patients based on clinical retrospective analysis and bioinformatics study
- ADAMTS13, von Willebrand Factor, Platelet Microparticles, Factor VIII, and Impact of Somatic Mutations in the Pathogenesis of Splanchnic Vein Thrombosis Associated with BCR-ABL-Negative Myeloproliferative Neoplasms
- Analysis of CHIP-Related Mutation and Risk of Cardio-Cerebrovasculars Events in Patients with Myeloproliferative Neoplasms
- Analysis of the factors influencing the severity of coronavirus disease 2019 in patients with myeloproliferative neoplasms based on an online questionnaire
- Assessing haematological parameter and probable toxicity analysis in two coastal fish species at harbouring areas of digha coastal belt, West Bengal, India
- Assessing haematological parameters and probable toxicity analysis in two coastal fish species at harbouring areas of Digha coastal belt, West Bengal, India
- Association between elevated white blood cell counts and thrombotic events in polycythemia vera: analysis from REVEAL
- Association of JAK2V617F allele burden and clinical correlates in polycythemia vera: a systematic review and meta-analysis
- Bibliometric analysis of worldwide research on Polycythemia Vera in the 21st century
- Broad next generation integrated sequencing of myelofibrosis identifies disease-specific and age-related genomic alterations
- Calreticulin and JAK2V617F driver mutations induce distinct mitotic defects in myeloproliferative neoplasms
- Clinical Features and Long-Term Outcomes of a Pan-Canadian Cohort of Adolescents and Young Adults with Myeloproliferative Neoplasms: A Canadian MPN Group Study
- Clinical Insights and Dermatological Recommendations for Non-Melanoma Skin Cancers (NMSCs) in Long-Term Hydroxyurea (HU) Therapy
- Co-occurrence of <em>JAK2-V617 F</em> mutation and <em>BCR::ABL1</em> translocation in chronic myeloproliferative neoplasms: a potentially confounding genetic combination
- Common clonal origin of three distinct hematopoietic neoplasms in a single patient: B-cell lymphoma, T-cell lymphoma, and polycythemia vera
- Conventional Cytogenetic Analysis and Array CGH + SNP Identify Essential Thrombocythemia and Prefibrotic Primary Myelofibrosis Patients Who Are at Risk for Disease Progression
- Cytoreductive therapy in younger adults with polycythemia vera: a meta-analysis of safety and outcomes
- Decreased patency of transjugular intrahepatic portosystemic shunts performed for splanchnic vein thrombosis in patients with myeloproliferative neoplasms
- Differences in Clinical Outcomes Between Hydroxyurea-Resistant and -Intolerant Polycythemia Vera Patients
- Direct and indirect costs for patients with myeloproliferative neoplasms
- DNMT3A/TET2/ASXL1 Mutations are an Age-independent Thrombotic Risk Factor in Polycythemia Vera Patients: An Observational Study
- Does Double Mean Trouble? Coexistence of Myeloproliferative and Lymphoproliferative Neoplasms
- Effective Management of Polycythemia Vera With Ropeginterferon Alfa-2b Treatment
- Effects of hemoglobin concentration on retinochoroidal vascular plexuses: an optical coherence tomography angiography study
- Erythrocytosis and CKD
- Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management
- Evaluation of Absolute Neutrophil, Lymphocyte and Platelet Count and Their Ratios as Predictors of Thrombotic Risk in Patients with Prefibrotic and Overt Myelofibrosis
- Evaluation of Janus Kinase 2 Exon 12 Mutations in Patients With JAK2V617F-negative Polycythemia Vera
- Evaluation of secondary malignancies in a large series of mycosis fungoides
- Exploring hematological alterations and genetics linked to SNV rs10974944 in myeloproliferative neoplasms among Amazon patients
- Exposure-efficacy and exposure-safety analyses of ropeginterferon alfa-2b treatment in patients with polycythaemia vera
- Extensive Hepatic Infarction due to Polycythemia Vera
- Extreme erythrocytosis in a cat reverts after short-term treatment with hydroxyurea and the cat remains healthy for years
- Factor VII Deficiency in Systemic Mastocytosis with an Associated Myeloid Neoplasm
- Genomic classification and outcomes of young patients with polycythemia vera and essential thrombocythemia according to the presence of splanchnic vein thrombosis and its chronology
- Glycated hemoglobin (HbA1c) and thrombotic risk in polycythemia vera and essential thrombocythemia
- Hemangioblastoma: An Uncommon Cause of Polycythemia in a Child
- Hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib in clinical practice
- How I manage polycythemia
- HSR24-156: Treatment Patterns and Blood Count Control in 10,112 Patients With Polycythemia Vera Managed at Community Practices in the United States
- Idiopathic erythrocytosis: a germline disease?
- Impact of Hydroxyurea to Treat Haematological Disorders on Male Fertility: Two Case Reports and a Systematic Review
- In silico trial for the assessment of givinostat dose adjustment rules based on the management of key hematological parameters in polycythemia vera patients
- In vivo ablation of NFκB cascade effectors alleviates disease burden in myeloproliferative neoplasms
- Inflammation as a cause of acute myocardial infarction in patients with myeloproliferative neoplasm
- Insights into the role of JAK2-I724T variant in myeloproliferative neoplasms from a unique cohort of New Zealand patients
- Interferons in the treatment of myeloproliferative neoplasms
- Ischemic stroke as an initial performance of polycythemia vera in young adults: A case report and literature review
- JAK2V617F drives gut microbiota differences in patients with myeloproliferative neoplasms
- Late Presentation of Pseudophakic Macula Edema from Oral Kinase Inhibitors: A Case Series and Literature Review
- Late-Onset Hydroxyurea-Induced Melanonychia and Tongue Hyperpigmentation in a Patient With Polycythemia Vera: A Case Report
- Molecular Genetic Profile of Myelofibrosis: Implications in the Diagnosis, Prognosis, and Treatment Advancements
- Myelofibrosis: Current unmet needs, emerging treatments, and future perspectives
- Myeloproliferative Neoplasms: Diseases Mediated by Chronic Activation of Signal Transducer and Activator of Transcription (STAT) Proteins
- Neutrophil-to-lymphocyte ratio and all-cause mortality with and without myeloproliferative neoplasms-a Danish longitudinal study
- Novel germline JAK2<sup>R715T</sup> mutation causing PV-like erythrocytosis in 3 generations. Amelioration by Ropeg-Interferon
- Obstructive Sleep Apnea Does Not Exclude Polycythemia Vera: A Case Report
- Polycythemia vera and essential thrombocythemia of intermediate-age: A real-life, multicenter analysis of first-line treatment approach
- Polycythemia Vera: Barriers to and Strategies for Optimal Management
- Post polycythemia vera myelofibrosis with myelodysplastic-like progression in a patient with chronic lymphocytic leukemia
- Proinflammatory phenotype of iPS cell-derived JAK2 V617F megakaryocytes induces fibrosis in 3D in vitro bone marrow niche
- Prolonged Proton Pump Inhibitor Use and Thrombohemorrhagic Risk in Essential Thrombocythemia and Polycythemia Vera Patients Treated with Long-Term Aspirin: A Pilot Study
- Real-World Electronic Medical Records Data Identify Risk Factors for Myelofibrosis and Can Be Used to Validate Established Prognostic Scores
- Real-world status of treatment for lymphoid neoplasms developed during the course of myeloproliferative neoplasms in Japan
- Recombinant interferon alfa in BCR/ABL-negative chronic myeloproliferative neoplasms
- Red Blood Cell Contribution to Thrombosis in Polycythemia Vera and Essential Thrombocythemia
- Retinal Vessel Analysis and Microvascular Abnormalities in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms
- Retraction Note: Microrheological disorders in patients with polycythemia vera suffered acute ischemic stroke
- Retraction: In Vivo Monitoring of Polycythemia Vera Development Reveals Carbonic Anhydrase 1 as a Potent Therapeutic Target
- Risk factors for disease progression and treatment goals in polycythemia vera
- Risk of thrombosis, hemorrhage and leukemic transformation in patients with myeloproliferative neoplasms: A nationwide longitudinal cohort study
- ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options
- Ropeginterferon alfa-2b treatment in a young patient with multi-refractory polycythemia vera and double JAK2 gene mutation: a case report
- Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera
- Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera
- Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the "RAMP" Italian multicenter prospective study
- Ruxolitinib associated psoas muscle tuberculosis abscess in a primary myelofibrosis woman: A case report and literature review
- Secondary polycythemia in acutely ill COVID-19 patients is associated with higher mortality but not markedly higher thrombotic risk
- SHP2 inhibition displays efficacy as a monotherapy and in combination with JAK2 inhibition in preclinical models of myeloproliferative neoplasms
- SOHO State of the Art Update and Next Questions: Novel Therapies for Polycythemia Vera
- Spatial Mapping of Hematopoietic Clones in Human Bone Marrow
- The effect of polycythemia vera on choroidal thickness and retrobulbar blood flow
- The personal impact of living with a myeloproliferative neoplasm
- The Role of DNA Repair (<em>XPC</em>, <em>XPD</em>, <em>XPF</em>, and <em>XPG)</em> Gene Polymorphisms in the Development of Myeloproliferative Neoplasms
- The triple A model (age, absolute neutrophil count, absolute lymphocyte count-AAA) predicts survival and thrombosis in polycythemia vera
- Thromboembolic events, major bleeding and mortality in essential thrombocythaemia and polycythaemia vera-A matched nationwide population-based study
- Transcription factor 3 is dysregulated in megakaryocytes in myelofibrosis
- Treatment outcome and germline predictive factors of ropeginterferon alpha-2b in myeloproliferative neoplasm patients
- Two Novel Genetic Variants Involved in the Oxygen Sensing Pathway in JAK2-unmutated Erythrocytosis
- Understanding the role of red blood cells in venous thromboembolism: A comprehensive review
- Updated threshold, renewed problems: should the diagnostic criteria of polycythemia vera be reconsidered? A retrospective cross-sectional cohort study